Editas Medicine Stock Analysis

EDIT Stock  USD 10.77  0.24  2.28%   
The main objective of Editas Medicine stock analysis is to determine its intrinsic value, which is an estimate of what Editas Medicine is worth, separate from its market price. There are two main types of Editas Medicine's stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect Editas Medicine's performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of Editas Medicine's stock to identify patterns and trends that may indicate its future price movements.
The Editas Medicine stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Editas Medicine is usually not traded on Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day. Editas Stock trading window is adjusted to America/New York timezone. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Editas Medicine's ongoing operational relationships across important fundamental and technical indicators.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Editas Medicine. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product.
For more information on how to buy Editas Stock please use our How to Invest in Editas Medicine guide.

Editas Stock Analysis Notes

About 67.0% of the company shares are held by institutions such as insurance companies. The book value of Editas Medicine was currently reported as 4.41. The company recorded a loss per share of 2.69. Editas Medicine had not issued any dividends in recent years. Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts. Editas Medicine operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 264 people. To learn more about Editas Medicine call Gilmore ONeill at 617 401 9000 or check out https://www.editasmedicine.com.

Editas Medicine Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Editas Medicine's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Editas Medicine or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Editas Medicine had very high historical volatility over the last 90 days
The company reported the previous year's revenue of 19.71 M. Net Loss for the year was (220.43 M) with loss before overhead, payroll, taxes, and interest of (155.25 M).
Editas Medicine currently holds about 452.56 M in cash with (177.35 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.59.
Roughly 67.0% of the company shares are held by institutions such as insurance companies
Latest headline from news.google.com: Is Editas Medicine Inc Stock at the Top of the Biotechnology Industry - InvestorsObserver

Editas Medicine Upcoming and Recent Events

Earnings reports are used by Editas Medicine to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Editas Medicine previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
28th of February 2024
Upcoming Quarterly Report
3rd of May 2024
Next Financial Report
31st of December 2023
Next Fiscal Quarter End
28th of February 2024
Next Fiscal Year End
30th of September 2023
Last Quarter Report
31st of December 2022
Last Financial Announcement

Editas Largest EPS Surprises

Earnings surprises can significantly impact Editas Medicine's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Fiscal Date
Estimated EPS
Reported EPS
View All Earnings Estimates

Editas Medicine SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Editas Medicine prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Editas Medicine investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Editas Medicine specific information freely available to individual and institutional investors to make a timely investment decision.
22nd of November 2023
Financial Statements and Exhibits. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
3rd of November 2023
Financial Statements and Exhibits. Results of Operations and Financial Condition
10th of October 2023
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
4th of August 2023
Unclassified Corporate Event
2nd of August 2023
Financial Statements and Exhibits. Results of Operations and Financial Condition
15th of June 2023
Financial Statements and Exhibits. Other Events. Entry into a Material Definitive Agreement
9th of June 2023
Financial Statements and Exhibits. Other Events. Regulation FD Disclosure
5th of June 2023
Submission of Matters to a Vote of Security Holders

Editas Medicine Thematic Classifications

In addition to having Editas Medicine stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Pharmaceutical Products Idea
Pharmaceutical Products
USA Equities from Pharmaceutical Products industry as classified by Fama & French

Editas Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 879.63 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Editas Medicine's market, we take the total number of its shares issued and multiply it by Editas Medicine's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Editas Profitablity

Editas Medicine's profitability indicators refer to fundamental financial ratios that showcase Editas Medicine's ability to generate income relative to its revenue or operating costs. If, let's say, Editas Medicine is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Editas Medicine's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Editas Medicine's profitability requires more research than a typical breakdown of Editas Medicine's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2023
Return on Investment(49.42)(53.33)
Return on Average Assets(0.39)(0.42)
Return on Average Equity(0.50)(0.52)
Return on Invested Capital(0.62)(0.64)
Return on Sales(11.40)(12.30)

Management Efficiency

Editas Medicine has return on total asset (ROA) of (0.2519) % which means that it has lost $0.2519 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5033) %, meaning that it created substantial loss on money invested by shareholders. Editas Medicine's management efficiency ratios could be used to measure how well Editas Medicine manages its routine affairs as well as how well it operates its assets and liabilities. Return on Investment is likely to drop to -53.33 in 2023. Return on Average Assets is likely to drop to -0.42 in 2023. At this time, Editas Medicine's Total Liabilities is comparatively stable as compared to the past year. Liabilities Non Current is likely to gain to about 103.4 M in 2023, whereas Current Liabilities is likely to drop slightly above 53.8 M in 2023.
Last ReportedProjected for 2023
Book Value per Share 5.25  5.67 
Enterprise Value over EBIT(2.00)(2.16)
Enterprise Value over EBITDA(1.93)(2.08)
Price to Book Value 1.69  1.74 
Tangible Assets Book Value per Share 7.49  10.11 
Enterprise Value420.5 M431.6 M
Tangible Asset Value514.3 M493.1 M
The analysis of Editas Medicine's management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Editas Medicine's future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Editas Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.

Technical Drivers

As of the 4th of December, Editas Medicine shows the Downside Deviation of 3.82, mean deviation of 3.46, and Coefficient Of Variation of 1293.98. Editas Medicine technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to collect and analyze data for nineteen technical drivers for Editas Medicine, which can be compared to its rivals. Please confirm Editas Medicine information ratio, as well as the relationship between the potential upside and kurtosis to decide if Editas Medicine is priced favorably, providing market reflects its regular price of 10.77 per share. Given that Editas Medicine has jensen alpha of 0.3461, we urge you to verify Editas Medicine's prevailing market performance to make sure the company can sustain itself at a future point.

Editas Medicine Price Movement Analysis

Execute Study
The output start index for this execution was thirty-five with a total number of output elements of twenty-six. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Editas Medicine middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Editas Medicine. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

Editas Medicine Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Editas Medicine insiders, such as employees or executives, is commonly permitted as long as it does not rely on Editas Medicine's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Editas Medicine insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Editas Medicine Technical and Predictive Indicators

Editas Medicine Forecast Models

Editas Medicine's time-series forecasting models are one of many Editas Medicine's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Editas Medicine's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Editas Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Editas Medicine prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Editas shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Editas Medicine. By using and applying Editas Stock analysis, traders can create a robust methodology for identifying Editas entry and exit points for their positions.
Last ReportedProjected for 2023
EBITDA Margin(11.07)(11.95)
Gross Margin 0.90  0.89 
Profit Margin(11.18)(12.06)

Current Editas Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Editas analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Editas analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
Editas Medicine current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Editas analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Editas stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Editas Medicine, talking to its executives and customers, or listening to Editas conference calls.
Editas Analyst Advice Details

Editas Stock Analysis Indicators

Editas Medicine stock analysis indicators help investors evaluate how Editas Medicine stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Editas Medicine shares will generate the highest return on investment. By understating and applying Editas Medicine stock analysis, traders can identify Editas Medicine position entry and exit signals to maximize returns.
Begin Period Cash Flow207.4 M
Common Stock Shares Outstanding68.7 M
Total Stockholder Equity360.7 M
Total Cashflows From Investing Activities114.1 M
Property Plant And Equipment Net59.2 M
Cash And Short Term Investments437.4 M
Cash141.5 M
Accounts Payable9.5 M
Net Debt-97.6 M
50 Day M A7.9195
Total Current Liabilities60.1 M
Other Operating Expenses245.7 M
Non Current Assets Total157.6 M
Common Stock Total Equity7000.00
Non Currrent Assets Other5.3 M
Stock Based Compensation29.3 M
When determining whether Editas Medicine is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Editas Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Editas Medicine Stock. Highlighted below are key reports to facilitate an investment decision about Editas Medicine Stock:
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Editas Medicine. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product.
For more information on how to buy Editas Stock please use our How to Invest in Editas Medicine guide.
You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.

Complementary Tools for Editas Stock analysis

When running Editas Medicine's price analysis, check to measure Editas Medicine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Editas Medicine is operating at the current time. Most of Editas Medicine's value examination focuses on studying past and present price action to predict the probability of Editas Medicine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Editas Medicine's price. Additionally, you may evaluate how the addition of Editas Medicine to your portfolios can decrease your overall portfolio volatility.
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
List of equity sectors categorizing publicly traded companies based on their primary business activities
Is Editas Medicine's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Editas Medicine. If investors know Editas will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Editas Medicine listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
Revenue Per Share
Quarterly Revenue Growth
Return On Assets
Return On Equity
The market value of Editas Medicine is measured differently than its book value, which is the value of Editas that is recorded on the company's balance sheet. Investors also form their own opinion of Editas Medicine's value that differs from its market value or its book value, called intrinsic value, which is Editas Medicine's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Editas Medicine's market value can be influenced by many factors that don't directly affect Editas Medicine's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Editas Medicine's value and its price as these two are different measures arrived at by different means. Investors typically determine if Editas Medicine is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Editas Medicine's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.